Equities research analysts predict that Neon Therapeutics Inc (NASDAQ:NTGN) will post ($0.67) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Neon Therapeutics’ earnings. The lowest EPS estimate is ($0.70) and the highest is ($0.64). The business is expected to issue its next quarterly earnings report on Monday, February 11th.
On average, analysts expect that Neon Therapeutics will report full year earnings of ($5.17) per share for the current fiscal year, with EPS estimates ranging from ($5.50) to ($4.84). For the next financial year, analysts anticipate that the company will report earnings of ($3.06) per share, with EPS estimates ranging from ($3.44) to ($2.70). Zacks’ EPS averages are a mean average based on a survey of research analysts that cover Neon Therapeutics.
Neon Therapeutics (NASDAQ:NTGN) last posted its quarterly earnings data on Monday, November 12th. The company reported ($0.67) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.12.
NTGN has been the subject of a number of analyst reports. LADENBURG THALM/SH SH initiated coverage on shares of Neon Therapeutics in a research report on Monday, October 1st. They issued a “buy” rating and a $20.00 price objective for the company. Zacks Investment Research raised shares of Neon Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 price objective for the company in a research report on Friday, November 16th. Five investment analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus target price of $18.08.
A number of hedge funds have recently modified their holdings of the stock. TRV GP Iii LLC acquired a new position in Neon Therapeutics during the second quarter worth approximately $122,745,000. FMR LLC acquired a new position in Neon Therapeutics during the second quarter worth approximately $26,746,000. Partner Fund Management L.P. acquired a new position in Neon Therapeutics during the second quarter worth approximately $10,771,000. Partner Investment Management L.P. increased its position in Neon Therapeutics by 32,903.8% during the third quarter. Partner Investment Management L.P. now owns 832,355 shares of the company’s stock worth $5,841,000 after purchasing an additional 829,833 shares during the last quarter. Finally, Hillhouse Capital Management Ltd. acquired a new position in Neon Therapeutics during the second quarter worth approximately $8,969,000. 71.09% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ:NTGN traded down $0.15 during trading on Monday, reaching $5.73. The stock had a trading volume of 67,857 shares, compared to its average volume of 87,450. Neon Therapeutics has a fifty-two week low of $5.51 and a fifty-two week high of $16.23.
About Neon Therapeutics
Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.
See Also: Depreciation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.